Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phthalimide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.71 |
| ▸ | CASP3 | P42574 | 3/20 | 0.60 |
| ▸ | CASP7 | P55210 | 2/20 | 0.60 |
| ▸ | CASP6 | P55212 | 2/20 | 0.60 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.60 |
| ▸ | CASP2 | P42575 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 3/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | FER | P16591 | 1/20 | 0.46 |
| ▸ | LTK | P29376 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalimide SCHEMBL10495310 | 0.91 | GSK3B (0.65) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL28193801 | 0.90 | GSK3B (0.79) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL28946377 | 0.88 | GSK3B (0.75) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL2452324 | 0.88 | GSK3B (0.75) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL11703668 | 0.86 | GSK3B (0.71) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL5667903 | 0.86 | GSK3B (0.58) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL23063638 | 0.85 | GSK3B (0.88) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL28399928 | 0.85 | GSK3B (0.62) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL11040503 | 0.84 | GSK3B (1.00) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL29366030 | 0.84 | GSK3B (1.00) | GSK3BCASP3CASP7CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108484671-A | Phospholipid analogues, Preparation method and use with camptothecine structural unit | 东北林业大学 | 2018-09-04 | — | — | CN | claimed |
| CN-103897062-B | A kind of preparation method of the yolk antibody of anti-methamphetamine | JIANGHAN UNIVERSITY (CN) | 2016-11-30 | — | — | CN | claimed |
| EP-1028940-B1 | PROCESS TO PRODUCE OXAZOLIDINONES | PHARMACIA & UPJOHN CO LLC (US) | 2007-04-18 | — | — | EP | claimed |
| EP-1772453-A1 | Process to produce Oxazolidinones | Pharmacia & Upjohn Company LLC (US) | 2007-04-11 | — | — | EP | claimed |
| US-20040006238-A1 | Process to produce oxazolidinones | PHARMACIA & UPJOHN COMPANY | 2004-01-08 | — | — | US | claimed |
| US-20030216572-A1 | PROCESS TO PRODUCE OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY | 2003-11-20 | — | — | US | claimed |
| US-6613944-B2 | Reacting phthalimide with an epoxide in the presence of potassium phthalimide in DMF or DMAC to give a phthalimide alkylalcohol, deacylation with aqueous acid | PHARMACIA & UPJOHN COMPANY | 2003-09-02 | — | — | US | claimed |
| US-20030130509-A1 | PROCESS TO PRODUCE 3-CARBON AMINO ALCOHOL SALTS | PHARMACIA & UPJOHN COMPANY | 2003-07-10 | — | — | US | claimed |
| US-20030065219-A1 | PROCESS TO PRODUCE OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY | 2003-04-03 | — | — | US | claimed |
| US-20020095054-A1 | Process to produce oxazolidinones | PHARMACIA & UPJOHN COMPANY | 2002-07-18 | — | — | US | claimed |
| US-20020032348-A1 | Process to produce oxazolidinones | PEARLMAN BRUCE ALLEN (US) | 2002-03-14 | — | — | US | claimed |
| EP-1028940-A1 | PROCESS TO PRODUCE OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2000-08-23 | — | — | EP | claimed |
| WO-1999024393-A1 | PROCESS TO PRODUCE OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 1999-05-20 | — | — | WO | claimed |
| CN-103897062-B | A kind of preparation method of the yolk antibody of anti-methamphetamine | JIANGHAN UNIVERSITY (CN) | 2016-11-30 | — | — | CN | disclosed |
| CN-101248070-B | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-14 | — | — | CN | disclosed |
| CN-101248070-A | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-20 | — | — | CN | disclosed |
| WO-1999024393-A1 | PROCESS TO PRODUCE OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5817879-A | PEPTIDE ANTAGONIST | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-10-06 | — | — | US | disclosed |
| US-5550251-A | CROSSREACTIVE WITH PEPTIDES BOUND BY G-PROTEIN LINKED RECEPTORS; USED AS THERAPEUTICAL, DIAGNOSTIC, AND PROPHYLITIC | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1996-08-27 | — | — | US | disclosed |
| WO-1993011731-A2 | ALICYCLIC PEPTIDOMIMETICS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065219-A1 | PROCESS TO PRODUCE OXAZOLIDINONES | ADH1A, ADH5, ADH1C | GSK3B 729/4885CASP3 3839/4885CASP7 2727/4885 |
| US-20030130509-A1 | PROCESS TO PRODUCE 3-CARBON AMINO ALCOHOL SALTS | ADH1A, ADH5, ADH1C | GSK3B 947/4885CASP3 3912/4885CASP7 3672/4885 |
| US-20040006238-A1 | Process to produce oxazolidinones | ADH1A, ADH5, ADH1C | GSK3B 605/4885CASP3 3684/4885CASP7 2661/4885 |
| US-20020095054-A1 | Process to produce oxazolidinones | ADH1A, ADH5, ADH1C | GSK3B 729/4885CASP3 3839/4885CASP7 2727/4885 |
| US-20030216572-A1 | PROCESS TO PRODUCE OXAZOLIDINONES | ADH1A, ADH5, ADH1C | GSK3B 729/4885CASP3 3839/4885CASP7 2727/4885 |
| US-20020032348-A1 | Process to produce oxazolidinones | ADH1A, ADH5, ADH1C | GSK3B 729/4885CASP3 3839/4885CASP7 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.